United Therapeutics Corporation Convertible Notes Payable, Current
United Therapeutics Corporation (UTHR) had Convertible Notes Payable, Current of $900.00 thousand as of 2016-06-30, per its 10-Q filed 2016-07-28.
Discontinued › Balance Sheet › Liabilities › Notes Payable, Current
us-gaap:ConvertibleNotesPayableCurrent · last filed 2016-07-28
- 2016-06-30: Convertible Notes Payable, Current $900.00K.
- 2016-03-31: Convertible Notes Payable, Current $5.40M.
- 2015-12-31: Convertible Notes Payable, Current $5.40M; Convertible Notes Payable, Current as first filed $5.39M.
- 2015-09-30: Convertible Notes Payable, Current $30.02M.
| Period end | Convertible Notes Payable, Current | Convertible Notes Payable, Current as first filed |
|---|---|---|
| 2016-06-30 | $900.00K 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $5.40M 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $5.40M 10-Q · filed 2016-07-28 | $5.39M 10-K · filed 2016-02-25 |
| 2015-09-30 | $30.02M 10-Q · filed 2015-10-27 | |
| 2015-06-30 | $32.28M 10-Q · filed 2015-07-28 | |
| 2015-03-31 | $115.22M 10-Q · filed 2015-04-28 | |
| 2014-12-31 | $126.41M 10-K · filed 2016-02-25 | |
| 2014-09-30 | $224.70M 10-Q · filed 2014-10-28 | |
| 2014-06-30 | $221.71M 10-Q · filed 2014-07-29 | |
| 2014-03-31 | $218.74M 10-Q · filed 2014-04-29 | |
| 2013-12-31 | $215.84M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $212.97M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $210.17M 10-Q · filed 2013-07-25 | |
| 2011-09-30 | $248.54M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $244.27M 10-Q · filed 2011-07-28 | |
| 2011-03-31 | $240.08M 10-Q · filed 2011-04-28 | |
| 2010-12-31 | $235.97M 10-K · filed 2012-02-28 | |
| 2010-09-30 | $231.93M 10-Q · filed 2010-10-28 | |
| 2010-06-30 | $227.98M 10-Q · filed 2010-07-28 | |
| 2009-12-31 | $220.27M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |